Infertility

The safety of fertility drugs has been a concern to physicians and patients alike. A new study assessing fertility drugs and breast cancer risk has reassuring results.

Patients undergoing IVF do better with strong social support, but many of these patients feel isolated and don’t share their fertility struggles. Can mindfulness help?

Clinically meaningful data about stress and fertility has been reported by Longitudinal Investigation of Fertility and the Environment (LIFE) study researchers.

According to a recent study in Human Reproduction, women who produce a low number of oocytes during in vitro fertilization (IVF) seem to have an increased risk of miscarriage.

New research expected this year will bring about significant changes to clinical practice. Here, society leaders share what’s on their radar for 2014.

What research from the past year will have the most significant impact on women's health care? The leaders of five major ob/gyn societies weigh in.

A head-to-head comparison of salpingotomy and salpingectomy finds that removing the affected tube after an ectopic pregnancy doesn’t affect fertility as expected.

Physicians’ groups are urging ob/gyns to have difficult conversations with obese women about their weight. Here’s one example of how utter bluntness can be an effective tactic.

Gestational surrogacy in India is on the rise. How will this help or harm American couples and Indian surrogates?

The exposure of adolescent rats to tetrahydrocannabinol (THC) can alter neurobehavioral pathways in the next generation of offspring, even without direct exposure of progeny to the drug.

Successful endometriosis awareness campaigns are the key to beginning to control the disease, says Camran Nezhat, MD. Earlier diagnosis means a sooner return to a pain-free life for our patients.

Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization (IVF), according to researchers who say their data will help couples plan for the expenses they may incur. The current study is published online in the Journal of Urology ahead of the February 2014 print issue.

Whole genome sequencing of single egg cells for IVF to detect genetic defects could increase the chances of a healthy child if the results hold up in clinical trials.

A retrospective analysis of more than 400,000 U.S. births over nearly 6 years shows that delivery of triplets or more costs 20 times as much as a singleton. Published in The American Journal of Obstetrics and Gynecology, the report may be the first to look at medical expenses for both maternal and infant care associated with IVF-assisted pregnancy.

Asthmatic women may take longer to become pregnant, according to a new study published in The European Respiratory Journal.

Three IVF experts discuss what policy is best for infertility patients.

The Endocrine Society's new clinical practice guideline on polycystic ovary syndrome (PCOS) recommends diagnosis based on two of three key features of he condition. The advice, published in the Journal of Clinical Endocrinology and Metabolism, is aimed at reducing the need for ultrasound or hormone tests in patient evaluation.

Fertility treatment isn’t linked to an increased risk of ovarian cancer, according to a National Cancer Institute (NCI)-supported study spanning nearly two decades and published in Fertility and Sterility.

A fertility pen, redesigned to incorporate updates and new features developed from patient and provider feedback, has been FDA approved and will be available December 2013.

Ob/Gyns advocate for environmental policy changes to help safeguard reproductive health.

A new study finds promising evidence that a lung cancer drug, when combined with methotrexate, has potential to spare women with ectopic pregnancies from surgery.

The US Food and Drug Administration approved the new drug application (NDA) for Merck’s investigational fertility treatment corifollitropin alfa. Merck is seeking approval for the use of corifollitropin alfa in controlled ovarian stimulation (COS). If approved, the drug would be the first sustained follicular stimulant available in the United States.